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The management of type 2 diabetes mellitus (T2DM) 
has improved over the past decade, following the 
introduction of new antidiabetic agents that are able 
both to lower glucose levels effectively and not affect the 
patient’s cardiovascular risk profile adversely.[1] Some of 
these new therapeutic agents, the incretins, have been shown to lower 
traditional cardiovascular risk factors and also mitigate newly identified 
risk factors such as hypoglycaemia and weight gain, both of which often 
develop as adverse effects when tight glucose control is achieved.[2] The 
WHO Multinational Study of Vascular Disease in Diabetes showed 
that 52% of deaths in T2DM are attributed to cardiovascular disease.[3] 
Addressing both traditional and emerging cardiovascular risk factors by 
utilising a more composite glucose-lowering strategy may more readily 
achieve a comprehensive reduction in cardiovascular risk factors and a 
meaningful reduction in cardiovascular mortality. 
While long-term prospective cardiovascular outcome studies 
determining cardiovascular safety and/or protection for many of the 
incretin agents are still awaited, there is growing evidence that these 
agents are likely to be more effective than traditional antidiabetic 
agents in reducing the many long-term and costly complications of 
T2DM. Importantly, incretin therapy is able to treat high and low 
glucose levels more physiologically and is therefore likely to address 
the current global unmet needs in diabetes care, especially that of 
composite glucose lowering.[4]
In developing countries and regions, the dual burden of infectious 
diseases and T2DM has increased significantly among all social 
classes. In South Africa (SA) between 2000 and 2009, the prevalence 
of T2DM in the adult population over the age of 30 years doubled, 
accounting for more than two million cases in 2009.[5]
In sub-Saharan Africa, the incidence of T2DM is expected to 
grow by more than 100% over the next decade. This will pose an 
unprecedented challenge to healthcare resources.[6] If not effectively 
treated, the epidemic of T2DM has the potential to be as disruptive as 
the HIV pandemic in lowering life expectancy and reversing previous 
healthcare gains in Africa.[5-7]
This review focuses on the developments that have added to the 
available therapeutic armamentarium, and introduces data to support 
early rigorous but safe intervention so that the progressive adverse 
microvascular and in particular macrovascular complications may be 
reduced. This strategy is reviewed and evaluated particularly in the 
context of middle-income countries as defined by the World Bank.[8]
The epidemic of new cases of T2DM over the past two decades, 
particularly among younger patients, has resulted in a re-evaluation 
of clinical strategies to lower hyperglycaemia and reduce costly 
morbidity and mortality arising from poor glycaemic control. The 
first strategy involved a greater emphasis on using traditional 
agents (metformin, sulphonylureas and insulin) to intensify glucose 
control,[9] and the second the introduction of new antidiabetic agents 
to improve clinical care in order to address the shortcomings of 
traditional agents, enable the introduction of composite treatment, 
promote the long-term benefits of early and aggressive glucose-
lowering therapy, and thereby imprint and optimise metabolic legacy 
in the long term.
Intensive glucose control is limited  
by hypoglycaemia
Four major studies[9-13] have investigated the long-term benefits of 
intensive glucose control in T2DM as well as the adverse effects that 
can be expected from this approach (Table 1).
The landmark United Kingdom Prospective Diabetes Study (UKPDS) 
compared the effects of intensive blood glucose control using either 
sulphonylureas or insulin with conventional treatment on the risk of 
microvascular and macrovascular complications.[9] The aim of the 
intensive intervention was to target a fasting plasma glucose (FPG) 
level <6 mmol/L. The conventional therapy group was treated 
with diet and were only given drugs if there were hyperglycaemic 
symptoms or FPG rose >15 mmol/L. The intensive group’s overall risk 
of diabetes-related sequelae was reduced by 12% per annum, mainly 
driven by the 25% reduction in microvascular endpoints, including 
retinal photocoagulation. This was achieved at an increased risk of 
hypoglycaemia and greater weight gain than in the conventionally 
treated group (Table 2).
Cardiovascular events were not significantly reduced in the 
first 10 years of the study, but in the longer non-interventional 
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questionnaire-based follow-up for a further 
10 years, cardiovascular risk reduc tion 
reached significance (Fig. 1).[10] This 
finding was subsequently termed the 
‘legacy effect’ and has driven the clinical 
approach of early intensive treatment for 
T2DM, particularly in newly diagnosed 
younger individuals.
The Action to Control Cardiovascular Risk 
in Diabetes (ACCORD) study[11] was con-
ducted in the USA and Canada and compared 
intensive glucose control with lower HbA1c 
levels (<6%) with conventional therapy 
targeting HbA1c levels of 7.0 - 7.9%. The study 
included 20% African American patients and 
was conducted over a period of 3.5 years. 
The ACCORD study identified, for 
the first time, the potential harm of this 
intensive approach in patients with multiple 
cardiovascular risk factors, 35% of whom had 
experienced a cardiovascular event prior to 
entry into the study. This study was halted 
early after increased mortality was observed 
in the intensively treated group of patients. 
Patients were treated with sulphonylureas, 
rosiglitazone and insulin, and a very small 
percentage (12.0%) with the first available 
incretin mimetic, exenatide. Rates of hypo-
glycaemia were very high, with 10.5% of 
patients in the intensive therapy group 
experiencing severe hypoglycaemia requiring 
medical assistance. This was a threefold 
increase over the standard therapy group 
(3.5%). Also weight gain was much higher 
in the intensively treated group, with 28% of 
patients gaining >10 kg. The absolute increase 
in cardiovascular mortality has been shown to 
be directly proportional to the frequency and 
severity of hypoglycaemia.[14,15]
The Veterans Affairs Diabetes Trial 
(VADT),[12] a trial among male veterans with a 
mean age of 60 years and T2DM duration of 11.5 
years, also treated patients with conventional 
agents (metformin, glimepiride, rosiglitazone 
and insulin) for a period of 5.6 years. There 
was no difference in the rate of progression of 
microvascular complications, development of 
macrovascular complications or death. There 
was, however, a dramatic increase in the rate 
of sudden death in the intensively treated 
group. Severe hypoglycaemia in the intensively 
treated group was fourfold higher than in the 
conventionally treated group (Table 3).
The Action in Diabetes and Vascular Dis-
ease-Preterax and the Diamicron modif ied 
release Controlled Evaluation (ADVANCE) [13] 
trial included more than 11 000 patients with 
T2DM diagnosed at age 30 years and older, 
with diabetes-related vascular disease or an 
additional vascular risk factor; they were 
observed for a mean follow-up period of 5 
years. The average duration of diabetes was 8 
years, lower than in VADT (11.5 years) and 
ACCORD (10 years). The risk of developing 
microvascular complications was reduced, 
mainly as a result of a reduction in nephropathy 
or worsening nephropathy. There was no 
impact on macrovascular events in either the 
Table 1. Intensive glucose control (IGC) in T2DM
Study Protocol design
Benefits of intensive/ 
conventional therapy Complications




















13% reduction in all-
cause mortality
15% reduction in 
myocardial infarction
Not recorded
ACCORD[11] 10 000 patients 
with CV risk,  
62 years, 20% black
Median follow-up 
3.5 years




None Severe hypoglycaemia (10.5%) 
requiring medical assistance in 
intensive arm
16.2% requiring assistance in 
intensive arm
Weight gain >10 kg in 28% of 
intensively treated patients





if HbA1c not 
<6% in intensive 
arm, 9% in 
conventional arm
None Severe hypoglycaemia 203/100 
in patient-years in IGC: 
52/100 in standard therapy
Weight gain double in 
intensive arm v. conventional 
arm
ADVANCE[13] 11 140 patients, 
diabetes 
diagnosed at  





4.4 - 6.1 mmol/L, 
conventional 
group  
10 - 11 mmol/L
Reduced incidence of 
nephropathy
Severe hypoglycaemia 2.7% in 
IGC group v. 1.5%
No weight gain
CV = cardiovascular.
Table 2. Principal findings from intensive glucose control (IGC)
Early IGC induces a legacy effect of reduced microvascular and macrovascular events over subsequent 
years
IGC using sulphonylureas (glibenclamide, glimepiride, gliclazide) or insulin increases severe 
hypoglycaemic events two- to fourfold over conventional therapy
As the duration of type 2 diabetes increases, the rate of hypoglycaemic events increases
Hypoglycaemia is associated with increased cardiovascular mortality
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intensive or the conventional therapy arm. 
Hypoglycaemia was twofold higher in the 
intensive group, but overall was less frequent 
than in either VADT or ACCORD. There 
was no weight gain in the intensive arm. 
Severe hypoglycaemia, defined as a plasma 
glucose concentration of <2.8 mmol/L, was 
associated with a two- to threefold increase in 
cardiovascular mortality.[16] Therapy did not 
include any incretin mimetics, but did include 
thiazolidinediones.
These intensive glucose control studies 
have shown that hypoglycaemia is an 
important factor in limiting the anticipated 
cardiovascular benefits that should accrue 
from tight glucose control (Table 2).
Hypoglycaemia and 
antidiabetic treatment
An acute hypoglycaemic event induces insulin 
suppression followed by the release of counter-
regulatory hormones, glucagon and epinephrine 
(acutely) and growth hormone plus cortisol 
(chronically). The magnitude of the counter-
regulatory response is attenuated and delayed 
with increasing age (>60 years). The response in 
older individuals is also triggered at lower glucose 
levels than in the young healthy population.[17]
The counter-regulatory response in T2DM 
occurs at a higher threshold of glucose than in 
type 1 DM, allowing some degree of protection 
against hypoglycaemia. However, when insulin 
is given to improve glucose control in T2DM, 
the counter-regulatory response resets to 
a lower glucose level. The development of 
hypoglycaemia-associated autonomic failure 
also occurs in T2DM,[18] and is accompanied 
by a further drop in the glucose level that 
triggers counter-regulation. This hypoglycaemic 
un aware ness can be partially reversed by avoid-
ing further hypoglycaemic events.[19]
Initially, hypoglycaemia limits the achieve-
ment of target glucose control, and in 
particular limits attainment of longer-term 
cardiovascular benefit in terms of the legacy 
effect.
Hypoglycaemia and the  
cardiovascular system
Greater clarity is emerging with regard 
to the mechanisms under lying the dele-
terious effects of hypoglycaemia on the 
cardiovascular system, as illustrated in Fig. 2. 
Hypoglycaemia and cardiac 
ischaemia 
Studies using continuous glucose monitoring and 
simultaneous cardiac Holter monitoring have 
shown that hypoglycaemia in T2DM is more 
likely to be associated with cardiac ischaemia and 
angina symptoms than with hyperglycaemia.[20]
Even prior to the development of coronary 
artery disease (CAD) in T2DM, myocardial 
blood flow (MBF) reserve is reduced as a result 
of microangiopathy, which is attributed to 
poor glycaemic con trol.[21] The baseline MBF 
was shown to be comparable among T2DM 
patients with microvascular angina, T2DM 
patients with CAD and control subjects. 
However, the MBF (not peak stress), measured 
during dipyridamole administration, was 
significantly lower in T2DM patients with 
microvascular angina than in patients with 
macrovascular disease.[22]
It is therefore plausible that early control 
of glucose in T2DM can also limit the 
development of coronary microangiopathy; 
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Fig. 1. Legacy effect of UKPDS study.[10] (*p<0.05, **p=0.052: intensive v. conventional treatment.)
Hypoglycaemia
Thrombosis
•  Increased platelet count
•  Increased coagulation
•  Factor VIII and brinogen
•  Increased platelet aggregation and
   activation
Myocardial injury
•  Decreased MBFR
•  Increased oxygen demand, cardiac
   output, workload
Conduction disturbances
•  Increased QT interval and risk of
   sudden cardiac death
•  Increased catecholamines
•  Hypokalaemia
Endothelial dysfunction
•  Increased inammation
•  Increased oxidative stress
•  Vasconstruction
Fig. 2. Hypoglycaemia and the cardiovascular system.
Table 3. Comparison of severe hypoglycaemia (<2.8 mmol/L) in ACCORD, VADT  
and ADVANCE trials
ACCORD[11]
% of patients with events
VADT[12]
Events per 100 patient-years
ADVANCE[13]
% of patients with events
Conventional 5.0 Conventional 50 Conventional 1.5
Intensive 16.2 Intensive 200 Intensive 2.7
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Hypoglycaemia and cardiac arrhythmias 
Hypoglycaemia is known to affect the electrocardiograph (ECG), resul-
ting in lengthening of the QT interval in both type 1 and type 2 DM.[23]
While the exact mechanism is not accurately defined, investigations 
using continuous interstitial glucose and ambulatory ECG monitoring 
are improving the understanding of the roles of hypoglycaemia-induced 
sympathetic neural activation, hypoglycaemia and defective counter-
regulation. A recent evaluation in insulin-treated T2DM using this technique 
has shown a greater frequency of hypoglycaemia-induced bradycardia and 
atrial and ventricular ectopic counts during the night ascompared with the 
day, and compared with periods of euglycaemia.[24] Excessive compensatory 
vagal activation after the counter-regulatory phase may be responsible for 
the bradycardia and arrhythmias. QT prolongation only reached significance 
during the day in a 2014 study by Chow et al.[24] of diabetic patients at 
cardiovascular risk.
Recent research on patients with long-QT syndrome due to loss-of-
function mutations in KCNZQ1 has shown that these patients also have 
hyperinsulinaemia and symptomatic hypoglycaemia, caused by altered 
potassium channels in cardiomyocytes and pancreatic beta cells.[25] 
This is the first identification of an extracardial phenotype in KCNZQ1 
and long-QT syndrome patients. The episodes of syncope, ventricular 
tachyarrhythmias and cardiac arrest may also therefore be the result of 
hypoglycaemia and low potassium levels in these patients and not only 
a consequence of the genetically produced disturbance in conduction.
Hypoglycaemia and thrombosis
Acute hypoglycaemia alters platelet and clotting factors, producing a 
procoagulant and prothrombotic state. In a study by Dalsgaard-Nielsen 
et al.,[26] platelet counts were decreased significantly and activated 
partial thromboplastin time was also reduced during insulin-induced 
hypoglycaemia. Fibrinogen and factor VIII levels were substantially 
increased in the diabetes patients compared with healthy controls. 
Overall, there was a two- to threefold increase in platelet 
aggregation and a 50% increase in factor VIII concentrations in the 
diabetic patients.
Hypoglycaemia and endothelial dysfunction
Endothelial dysfunction is the early predictor of atherosclerosis.[27] 
In diabetes, endothelial dysfunction is primarily caused by oxidative 
stress and increased formation of advanced glycation end-products. 
Oxidative stress reduces nitrous oxide bioavailability with increased 
free radical superoxides promoting vascular smooth-muscle cell 
proliferation and inflammation. Endothelin-1, the most potent 
vasoconstrictor of blood vessels, has also been shown to increase 
following hypoglycaemia.[28] These vascular events, combined with an 
increase in high-sensitivity C-reactive protein and other inflammatory 
markers in diabetic patients experiencing hypoglycaemia,[29] create a 
favourable environment for the development of atherosclerosis.
These findings are particularly important to middle-income 
countries with their epidemiologically younger populations, typically 
higher rates of complications from T2DM and inadequate resources 
for costly hospitalisation following adverse cardiovascular and other 
vascular events. There is a need to establish normoglycaemia to 
induce the long-term benefit of metabolic legacy. This is more readily 
achieved if composite therapy is available.
Type 2 diabetes complications and 
hypoglycaemia in Africa and non-
Western developing countries
A substantially higher than expected diabetes prevalence was 
found among urban-dwelling black South Africans in a 2008/2009 
community-based study conducted in predominantly black African 
areas of Cape Town compared with a similar prevalence study 
undertaken two decades earlier.[30,31] The age-standardised prevalence 
was the highest reported in sub-Saharan Africa. Of particular 
importance is the finding that prevalence rose extremely sharply in 
people aged >45 years; 20 - 25% of people screened and found to be 
diabetic were in the younger economically active group aged 45 - 64 
years. More than 50% of the diabetes cases identified were previously 
unknown to the participants. The high rates of impaired glucose 
tolerance and obesity will ensure a continuing and ever-increasing 
diabetes caseload for SA healthcare facilities.
Diabetes complications, including macrovascular sequelae, will be 
extensive in middle-income countries. In an evaluation of the non-
fatal disease burden caused by T2DM in 2009 in SA, the years lost 
to disability (YLD) were modelled and estimated at 78 900.[5] These 
included 8 000 new cases of blindness, 2 000 new amputations, 7 000 
strokes and 5 500 YLD attributable to ischaemic heart disease. 
A systematic review of diabetes prevalence and its complications 
in North Africa (Morocco, Algeria, Tunisia, Libya, Egypt, Sudan, 
South Sudan and Western Sahara) also highlighted that undiagnosed 
diabetes is common. The prevalence of complications among known 
and treated diabetic patients ranged from 8% to 42% for retinopathy, 
21% to 22% for albuminuria, 6.7% to 46.3% for nephropathy and 
21.9% to 60% for neuropathy.[32]
Data on the influence of hypoglycaemia on diabetes-related outcomes 
in middle-income countries are rare. There are no SA or African data. 
A single traceable study was found on the influence of hypoglycaemia 
on total mortality and cardiovascular events in a non-Western, recently 
developed country, Taiwan, conducted using the Taiwan National Health 
Insurance medical records.[33] The study included 77 661 new cases of 
diabetes diagnosed between 1998 and 2009. From this database, 500 
patients were identified with severe hypoglycaemic events, who were 
hospitalised, and 1 344 patients were treated for mild hypoglycaemia, on 
an outpatient basis. These patients were matched to a cohort of patients 
who did not experience hypoglycaemic events. 
This real-world study showed that clinically driven hypoglycaemia 
increased adverse cardiovascular outcomes and hospitalisation 
approximately twofold. Adverse events occurred primarily in the first 
year that followed the hypoglycaemic event.
Strategies to prevent hypoglycaemia
Effective approaches to reduce hypoglycaemia include patient 
education, dietary and exercise modification, regular glucose 
monitoring by the patient and the use of safer glucose-lowering 
therapies by the clinician.[34]
Medication adjustment to minimise the  
impact of hypoglycaemia 
The Working Group of the American Diabetes Association (ADA) and 
the Endocrine Society advise clinicians to substitute sulphonylureas 
with other classes of oral agents or with glucagon-like peptide 1 
(GLP-1) analogues in patients experiencing hypoglycaemic events. 
In cases of frequent and recurrent hypoglycaemia, which leads to 
hypoglycaemic unawareness, this strategy of using oral agents that 
cause limited hypoglycaemia is even more important.
Incretin-based therapies, such as the GLP-1 analogues and the 
dipeptidyl peptidose-4 (DPP-4) inhibitors carry an overall lower risk of 
hypoglycaemia than the sulphonylureas and insulin and are favoured 
agents to minimise the extent of hypoglycaemia while still ensuring that 
patients reach appropriate glucose control targets.[35] The incretins and 
DPP-4s appear in the Society for Endocrinology, Metabolism and Diabetes 
of South Africa management of diabetes guideline,[36] and while available 
in the private sector are not available in the state sector owing to their cost. 
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Contemporary evidence-based guidelines for treatment 
of T2DM patients in middle-income countries and their 
impact on hypoglycaemic risk
Expert guidance for the management of T2DM has been issued by 
many professional international bodies; examples include the ADA/
European Association for the Study of Diabetes position state-
ment on individualised therapy[37] and the American Association of 
Clinical Endocrinologists guidelines.[38] While these developed-world 
guidelines provide useful guidance to best practice, developing non-
Western countries need to develop their own national guidelines as 
incorporation of local needs has been shown to make a substantial 
difference to standards of care.
A recent review of non-Western countries with identifiable 
national guidelines provides important insights on potential 
strategies for middle-income countries to avoid hypoglycaemia and 
improve outcomes in T2DM.[39] Overall, 33 non-Western countries 
have national guideline recommendations. Many are based on 
recent international guidelines but do not yet incorporate their 
individualised therapy approach.[39]
With regard to oral antidiabetic agents, 34% of the 33 countries 
monitored did not provide for the preferential use of specific 
sulphonylureas as second-line agents, but rather made provision 
for the use of any second oral agent such as the thiazolidinediones, 
DPP-4 inhibitors or alpha-glucosidase inhibitors. Some 30% of non-
Western guidelines (12 of 33) also suggest the option of injectable 
GLP-1 receptor agonists as an alternative to insulin as second-line 
therapy.
The SA guidelines[40] appear to follow international best practice, 
but still place traditional agents (metformin, sulphonylureas and 
insulin) in a preferred therapeutic silo. The SA positioning 
of newer agents (those with a minimal risk of hypoglycaemic 
complications or weight gain) as part of an alternative approach 
has reduced clinicians’ ability to prescribe these agents, as their 
availability is restricted in the formularies of both public and 
private funders.
Conclusion
It is clear that hypoglycaemia is a potential independent cardio-
vascular risk factor in diabetes. It is also evident that good glycaemic 
control at the outset is important for metabolic imprinting.
Current guidelines are inappropriate for many middle-income 
countries in the setting of primary healthcare. This is reducing the 
opportunity for the least-resourced level of care to achieve tight 
glucose control and obtain a legacy effect, as there is only access to 
traditional, not-fit-for-purpose agents. 
There is an urgent need to review primary healthcare policy 
in middle-resourced countries and provide a better selection of 
therapeutic agents so that tight control can be achieved without the 
complications of hypoglycaemia. A long-term health economic study 
is also needed to support the expansion of these policies in resource-
poor settings.
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